Trials / Completed
CompletedNCT00389415
Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes
A Multicenter, Open, Long Term Safety Study of 52 Weeks Treatment With Vildagliptin (100 mg qd) In Patients With Type 2 Diabetes (Extension Study of Study CLAF237A1303)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- —
Summary
This 52-week multicenter open-labeled extension study is designed to assess the long-term safety of vildagliptin (100 mg qd) in patients with Type 2 Diabetes. This extension study is open to patients who have completed core study CLAF237A1303.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin |
Timeline
- Start date
- 2006-10-01
- First posted
- 2006-10-18
- Last updated
- 2008-11-27
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00389415. Inclusion in this directory is not an endorsement.